Chronic Hemodialysis
Cardioprotective Hemodialysis
Despite significant improvements in the quality and efficacy of hemodialysis therapy in recent years, cardiovascular disease (CVD) remains the leading cause of death for dialysis patients.
Today, almost every other dialysis patient dies from cardiovascular complications.
Fresenius Medical Care is supporting nephrologists worldwide in reducing their patients’ risks for cardiovascular morbidity and mortality.
Innovative membranes like Fresenius Polysulfone and Helixone, modern monitoring devices like the Blood Volume Monitor, the Blood Temperature Monitor and Online Clearance Monitoring (OCM), ultrapure dialysis fluid prepared with DIASAFEplus and modern ONLINE hemodiafiltration systems support the reduction of CVD risk factors.
Moreover, one of our major goals in coming years is the development and implementation of innovative new therapies and products that further improve the cardiovascular prognosis of dialysis patients.
top